Navigation Links
QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV
Date:10/12/2010

loys nearly 90,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

QIAGEN Safe Harbour Statement

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the applied testing markets, clinical research markets and proteomics markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including fluctuations due to the level and timing of customers' funding, budgets, and other factors), our ability to obtain regulatory approval of our infectious disease panels, difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors' products, market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Co
'/>"/>

SOURCE QIAGEN
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics
2. QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests
3. QIAGEN Acquires Exclusive Licence for Key PI3K gene
4. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
5. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Second Quarter 2009 Financial Results Call Set for August 11
6. Plexus Awarded Development Contract With QIAGEN
7. QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata
8. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
9. QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations
10. SciQuest Announces Strategic Alliance with QIAGEN
11. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar will ... and clinical safety assessment in biosimilars. , Regulatory frameworks ... biosimilar drug development, however the complex nature of biopharmaceuticals ... safety and efficacy extremely challenging. Based on the specific ...
(Date:1/15/2014)... TX (PRWEB) January 15, 2014 More ... disease, and about 1 in 3 seniors will die ... source ). These jaw-dropping figures have shocked many Americans ... and, hopefully, help prevent these tragic age-related cognitive disorders. ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
(Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... (NYSE: CVD ) today reported GAAP earnings ... $0.35 per diluted share.  Included in fourth quarter results ... $0.10 of which relates to the completion of the ... the termination of a research products inventory supply agreement ...
... at the University of California, Riverside has identified a property ... to finding the Higgs boson in particle physics. Graphene, ... carbon atoms arranged in a hexagonal lattice. Because of ... themselves well to stacking. BLG is formed ...
... 2012 SPO Medical Inc. ( SPOM ... for use in portable monitoring devices, announced today an ... revenue generation strategy for fiscal 2012 primarily based on ... range of consumer wellness devices. SPO currently ...
Cached Biology Technology:Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 2Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 3Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 4Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 5Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 6Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 7Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 8Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 9Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 10Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 11Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 12Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 13Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 14Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 15Bilayer graphene works as an insulator 2Bilayer graphene works as an insulator 3SPO Updates Shareholders on 2012 Corporate Strategy 2SPO Updates Shareholders on 2012 Corporate Strategy 3
(Date:7/9/2014)... increasing concern about the prevalence of antibiotic-resistant illness, ... new pathway to disabling disease: blocking bacteria,s access ... showed how bacterial siderophore, a small molecule, captures ... bacterial growth as well as how the ... process. Their findings appear in a recent edition ...
(Date:7/9/2014)... some shark species may be able to cope with the ... temperatures. , The Arctic today is best known for its ... that. Roughly 53 to 38 million years ago during what ... similar to a huge temperate forest with brackish water, home ... hippo-like creatures, crocodiles and giant tortoises. Much of what is ...
(Date:7/9/2014)... but often can be defeated with antibiotics and then ... Now, scientists have built a new weapon against such pathogens ... journal ACS Applied Materials & Interfaces , their study ... them than medicine alone. , David Leong, Jianping Xie and ... undetectable in the human body or in places that antibiotics ...
Breaking Biology News(10 mins):Bacteria hijack plentiful iron supply source to flourish 2Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... 2010) BioSpace and BioMed Central are announcing ... today, a new online community for life science ... news. The new Career Network combines ... access publisher BioMed Central,s 1.2 million registrants to ...
... Girls in homes without a biological father are more ... a new study led by researchers at the University of ... to be published Sept. 17 in the Journal of ... related father in the home predicted earlier breast and pubic ...
... in environments ranging from the rainforests of the Amazon to ... this diversity would not be possible if the ancestors of ... green algal cousins. Moving onto dry land required major lifestyle ... turn helped change global climate and atmospheric conditions to conditions ...
Cached Biology News:Father absence linked to earlier puberty among certain girls 2Father absence linked to earlier puberty among certain girls 3Father absence linked to earlier puberty among certain girls 4Learning to live on land: How some early plants overcame an evolutionary hurdle 2
... priced, full ring small animal imaging PET ... microPET R4 low retail price, it outperfoms ... count rate performance, energy resolution, timing resolution, ... small animal PET (Positron Emission Tomography) imaging ...
... EVO series offers versatile liquid handling platforms ... a wide variety of life science applications.The ... base sizes (75, 100, 150 and 200 ... a platform that will advance with their ...
...
... microPET 220 utilizes utilizies CTI Molecular ... to superior resolution, sensitivty, and a ... user the flexibility to image multiple ... quality., microPET is a dedicated small ...
Biology Products: